TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.

Lin Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.